跳至主要内容
临床试验/NCT00625937
NCT00625937Unknown2 期

A Phase ll Trial of Induction Docetaxel and S-1 Followed by Concomitant Radiotherapy With Low-dose Daily Cisplatin in Locally Advanced Head and Neck Cancer

Yonsei University2 个研究点 分布在 2 个国家目标入组 46 人开始时间: 2006年11月最近更新:
适应症
相关药物

试验速览

阶段
2 期
入组人数
46
试验地点
2
主要终点
Objective response rate (complete or partial response) as assessed by RECIST criteria

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as docetaxel, S-1, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving more than one drug (combination chemotherapy) together with radiation therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving docetaxel and S-1 together with radiation therapy and low-dose cisplatin works in treating patients with stage III or stage IV head and neck cancer.

详细描述

OBJECTIVES:

Primary

  • To assess the response rate in patients with stage III or IV head and neck cancer treated with induction therapy comprising docetaxel and S-1 followed by radiotherapy and low-dose cisplatin.

Secondary

  • To assess the effect of this regimen on survival and locoregional and systemic control rates in these patients.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Objective response rate (complete or partial response) as assessed by RECIST criteria

次要结局

  • Toxicity as assessed by NCI CTCAE v3.0 criteria
  • Progression-free survival
  • Overall survival

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验